Protein Identified that May Point to Myeloma Patients Likely to Respond to Proteasome Inhibitors
Researchers at The University of Texas MD Anderson Cancer Center, in collaboration with other institutions, identified a gene called TJP1 that could help predict which multiple myeloma (MM) patients are most likely to respond and benefit from proteasome inhibitor drugs like bortezomib. The findings, “Tight Junction Protein…